Oliver Lagore Vanvalin Investment Group’s Sarepta Therapeutics SRPT Stock Holding History

Oliver Lagore Vanvalin Investment Group’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-90	Closed	-$11.2K	–	728
2024 Q3	$11.2K	Hold	90	–	–	﹤0.01%	407
2024 Q2	$14.2K	Hold	90	–	–	﹤0.01%	374
2024 Q1	$11.7K	Hold	90	–	–	﹤0.01%	399
2023 Q4	$8.68K	Sell	90 -7	-7%	-$671	﹤0.01%	439
2023 Q3	$11.8K	Buy	97 +7	+8%	+$791	﹤0.01%	415
2023 Q2	$10.3K	Hold	90	–	–	﹤0.01%	457
2023 Q1	$12.4K	Hold	90	–	–	0.01%	358
2022 Q4	$11.7K	Hold	90	–	–	0.01%	344
2022 Q3	$10K	Hold	90	–	–	0.01%	342
2022 Q2	$7K	Hold	90	–	–	﹤0.01%	380
2022 Q1	$7K	Buy	+90	New	+$6.89K	﹤0.01%	381

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Oliver Lagore Vanvalin Investment Group's SRPT Position: Q4 2024 in Review

Oliver Lagore Vanvalin Investment Group sold out of Sarepta Therapeutics (SRPT) in Q4 2024, closing a stake of 90 shares — an estimated $11.2K sold.

Oliver Lagore Vanvalin Investment Group first reported a position in SRPT in Q1 2022 and held it in 11 quarters. The position peaked at $14.2K in Q2 2024. 465 funds tracked by Wall St. Rank hold SRPT as of Q4 2024.

Oliver Lagore Vanvalin Investment Group reported no remaining Sarepta Therapeutics position as of Q4 2024 after selling out during the quarter.
Oliver Lagore Vanvalin Investment Group sold 90 Sarepta Therapeutics shares in Q4 2024, an estimated $11.2K.
Oliver Lagore Vanvalin Investment Group first reported a position in Sarepta Therapeutics in Q1 2022 and held it in 11 quarters.
Oliver Lagore Vanvalin Investment Group's Sarepta Therapeutics position peaked at $14.2K in Q2 2024.
465 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2024.

Based on Oliver Lagore Vanvalin Investment Group's 13F filing for Q4 2024, filed 1 Apr 2025.